Differential Diagnosis and Treatment Selection for Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Released On
November 12, 2019

Expires On
November 11, 2020

Media Type
Internet

Completion Time
60 minutes

Specialty
Allergy & Immunology, Pulmonology, Rheumatology

Topic(s)
EGPA

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by National Jewish Health.

 

Supported by an educational grant from GlaxoSmithKline.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the needs of pulmonologists, allergists and rheumatologists with an interest in better diagnosing and treating patients with EGPA and other eosinophilic diseases.

Program Overview

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome (CSS), is a hypereosinophilic syndrome (HES) characterized by eosinophilic vasculitis and one or more thefollowing: asthma, pulmonary infiltrates, sinusitis, and neuropathy. For patients with EGPA, the risk of permanent tissue and organ damage is significant. Although there are treatments available, patients with EGPA tend to remain dependent on glucocorticoid therapy and are prone to relapse.

Successful diagnosis of EGPA begins with a physician’s understanding of the HESs and ability to distinguish EGPA from other causes of eosinophilia and eosinophilic lung disease. This presents a challenge for many physicians because these disorders (aside from asthma) are relatively uncommon in everyday practice, even for pulmonary and allergy subspecialists.

This activity utilizes a patient perspective video to bring the challenges of the patient journey to life and a downloadable clinical diagnosis and treatment infographic along with a panel discussion between specialists who are experts in their fields of asthma, rheumatology and pulmonology who share their own experiences in diagnosing and treating patients with EGPA.

This material was originally presented as an adjunct symposium to the American College of Chest Physicians Annual Meeting (CHEST 2019) in New Orleans, Louisiana.

Program Resources

Click to view the following resources:
EGPA Infographic
EGPA Slide Deck

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify clinical features that distinguish EGPA from other eosinophilic lung diseases.
  • Review best practices for early evaluation and differential diagnosis of EGPA.
  • Select appropriate treatments for patients with EGPA.

Faculty

wechsler

Michael E. Wechsler, MD, MMSc (Program Chair and Presenter)

Director of The Cohen Family Asthma Institute
Professor of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO

khoury

Paneez Khoury, MD, MHSc, FAAAAI (Program Presenter)

Associate Research Physician
Allergy/Immunology
National Institutes of Health
Bethesda, Maryland

koening

Curry Koening, MD, MS (Program Presenter)

Director of the Vasculitis Clinic
Associate Professor
Rheumatology
University of Utah and Salt Lake City Veterans Administration
Salt Lake City, Utah

Physician Accreditation Statement

Physicians: National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

National Jewish Health designates this online educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all program faculty, content developers, CME approval committee, and those in position to control the content of this activity disclose any significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

All CME educational activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

Michael E. Wechsler, MD, MMSc

  • Consultant: AstraZeneca, Boehringer Ingelheim, Equillium, GlaxoSmithKline, Novartis, Sanofi Regeneron and Teva.
  • Investigator: AstraZeneca, GlaxoSmithKline, Sanofi Regeneron and Teva.

Paneez Khoury, MD, MHSc, FAAAAI

  • No financial relationships to disclose.

Curry Koening, MD, MS

  • Advisory Board: Genentech and Roch.

Planners and Reviewers

Andrea Harshman, MHA, CHCP, CMP-HC has no financial relationships to disclose.

Aubrey Shoe, MA has no financial relationships to disclose.

Stephanie Corder, ND, RN has no financial relationships to disclose.

Steve Frankel, MD has no financial relationships to disclose.

The patient featured in the video segment has no financial relationships to disclose.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

Method of Participation

There are no fees for participating and receiving CME credit for this activity. In order to receive credit for completing the online activity, participants must:

  1. Read the educational objectives and faculty disclosures.
  2. Complete the online activity.
  3. Complete and submit the online evaluation and post-test. Your certificate will be available immediately after submitting the evaluation and post-test.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.

By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

For CME questions, please contact National Jewish Health at proed@njhealth.org.

This material was originally presented as an adjunct symposium to the American College of Chest Physicians Annual Meeting (CHEST 2019) in New Orleans, Louisiana.